A promising new tuberculosis (TB) drug regimen, which could improve the treatment of drug sensitive TB and multi-drug resistant (MDR-)
TB Alliance, an international not-for-profit organization with the mission of developing improved tuberculosis (TB) treatments, announced the appointment of Mario
OPBIO Factory Co., Ltd. (OPBIO) has signed a research agreement with the Global Alliance for TB Drug Development (TB Alliance).
TB Alliance has launched a Phase 2B trial that will test the safety and effectiveness of a novel regimen with
TB Alliance announced today that pretomanid (pronounced: pree TOH mah nid) will be the generic, nonproprietary name for its novel
· REMoxTB confirmed the safety of moxifloxacin and its effect in killing TB; results pave way for further study of
Novartis has signed an exclusive worldwide licensing agreement with the Global Alliance for TB Drug Development (TB Alliance) for compounds
TB Alliance, a not-for-profit with the mission of discovering and developing better, faster and affordable treatments, announced the appointment of
TB Alliance, a not-for-profit organization with the mission of developing better, faster and affordable treatments for tuberculosis (TB), announced the
Researchers at the University of Sheffield, Imperial College London, and TB Alliance have found evidence that a large gap exists
